Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Hepatocyte growth factor promotes endogenous repair and functional recovery after spinal cord injury.

Authors: Kitamura, K  Iwanami, A  Nakamura, M  Yamane, J  Watanabe, K  Suzuki, Y  Miyazawa, D  Shibata, S  Funakoshi, H  Miyatake, S  Coffin, RS  Nakamura, T  Toyama, Y  Okano, H 
Citation: Kitamura K, etal., J Neurosci Res. 2007 Aug 15;85(11):2332-42.
Pubmed: (View Article at PubMed) PMID:17549731
DOI: Full-text: DOI:10.1002/jnr.21372

Many therapeutic interventions using neurotrophic factors or pharmacological agents have focused on secondary degeneration after spinal cord injury (SCI) to reduce damaged areas and promote axonal regeneration and functional recovery. Hepatocyte growth factor (HGF), which was identified as a potent mitogen for mature hepatocytes and a mediator of inflammatory responses to tissue injury, has recently been highlighted as a potent neurotrophic and angiogenic factor in the central nervous system (CNS). In the present study, we revealed that the extent of endogenous HGF up-regulation was less than that of c-Met, an HGF receptor, during the acute phase of SCI and administered exogenous HGF into injured spinal cord using a replication-incompetent herpes simplex virous-1 (HSV-1) vector to determine whether HGF exerts beneficial effects and promotes functional recovery after SCI. This treatment resulted in the significant promotion of neuron and oligodendrocyte survival, angiogenesis, axonal regrowth, and functional recovery after SCI. These results suggest that HGF gene delivery to the injured spinal cord exerts multiple beneficial effects and enhances endogenous repair after SCI. This is the first study to demonstrate the efficacy of HGF for SCI.

Annotation

Disease Annotations
Gene Ontology Annotations
Objects Annotated

Additional Information

 
CRRD Object Information
CRRD ID: 2317487
Created: 2010-04-07
Species: All species
Last Modified: 2010-04-07
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.